Litcius/Paper detail

Identification of FDA approved drugs and nucleoside analogues as potential SARS-CoV-2 A1pp domain inhibitor: An in silico study

Atul Kumar Singh, Prem Prakash Kushwaha, Kumari Sunita Prajapati, Mohd Shuaib, Sanjay Gupta, Shashank Kumar

2020Computers in Biology and Medicine57 citationsDOIOpen Access PDF

Topics & Concepts

In silicoSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Identification (biology)PharmacologyVirologyNucleoside analogueCoronavirus disease 2019 (COVID-19)NucleosideComputational biology2019-20 coronavirus outbreakMedicineChemistryBiologyStereochemistryInfectious disease (medical specialty)Internal medicineBiochemistryBotanyDiseaseOutbreakGeneSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesComputational Drug Discovery Methods
Identification of FDA approved drugs and nucleoside analogues as potential SARS-CoV-2 A1pp domain inhibitor: An in silico study | Litcius